The Metabolic Syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects

Author(s): Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, et al.


Aims: To evaluate the cardiovascular risk associated with the presence of the Metabolic Syndrome in Type 2 diabetic subjects.

Methods: Subjects with the Metabolic Syndrome, defined by WHO criteria, were identified in a large sample of non-insulin-treated Type 2 diabetic patients examined within the Verona Diabetes Complications Study (n = 946). At baseline and after a mean of 4.5 years follow-up, cardiovascular disease (CVD) was assessed by medical history, physical examination, electrocardiogram (ECG) and echo-duplex of carotid and lower limb arteries. Death certificates and medical records of subjects who died during the follow-up were scrutinized in order to identify CVD deaths. In statistical analyses, CVD was considered as an aggregate end-point, including fatal and non-fatal coronary, cerebrovascular and peripheral vascular disease as well as ischaemic ECG abnormalities and vascular lesions at the echo-duplex.

Results: The proportion of subjects with the Metabolic Syndrome was very high (92.3%). At the baseline, 31.7% of subjects were coded positive for CVD, which was more prevalent in subjects with the Metabolic Syndrome (32.9 vs. 17.8%, P = 0.005). Among subjects free of CVD at the baseline (n = 559), CVD events during the follow-up were significantly increased in patients with the Metabolic Syndrome as compared with those without it (19.9% vs. 3.9%, P < 0.001). Multiple logistic regression analysis showed that, along with sex, age, smoking and HbA1c, the presence of the Metabolic Syndrome independently predicted prevalent (OR 2.01, P = 0.045) and incident CVD (OR 4.89, P = 0.031).

Conclusions: In Type 2 diabetes, the presence of the Metabolic Syndrome is associated with an almost 5-fold increase in CVD risk.

Similar Articles

Global guidelines for type 2 diabetes

Author(s): IDF Clinical Guidelines Task Force

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

Author(s): Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, et al.

Computer modeling of diabetes and its complications

Author(s): The Mount Hood 4 Modeling Group

A clinical prediction rule for delirium after elective noncardiac surgery

Author(s): Marcantonio ER, Goldman L, Mangione CM, Ludwig LE, Muraca B, et al.

Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study

Author(s): van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, et al.

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)

Author(s): Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group

Risk factors for diabetic peripheral sensory neuropathy

Author(s): Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, et al.

Risk factors for renal dysfunction in type 2 diabetes: U

Author(s): Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR

Preserving renal function in adults with hypertension and diabetes: a consensus approach

Author(s): Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, et al.

Incidence and determinants of microalbuminuria in Koreans with type 2 diabetes

Author(s): Park JY, Kim HK, Chung YE, Kim SW, Hong SK, et al.

Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension

Author(s): Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, et al.